SEC For											<b></b>						
FORM 4 UNITED S					ATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549									OMB APPROVAL			
Section 16. Form 4 or Form 5 obligations may continue. See						NT OF CHANGES IN BENEFICIAL OWNERSHIP d pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940									OMB Number: 3235-0287   Estimated average burden    hours per response: 0.5		
1. Name and Address of Reporting Person <sup>*</sup> Serafin Andrew						2. Issuer Name and Ticker or Trading Symbol <u>Harmony Biosciences Holdings, Inc.</u> [ HRMY ]							cable) or (give title	erson(s) to Iss 10% Ov Other (s	vner		
(Last) C/O HAI	ast) (First) (Midd O HARMONY BIOSCIENCES HOLI			01	3. Date of Earliest Transaction (Month/Day/Year) 01/24/2024							X below) CHIE		below) GY OFFICE	R		
630 W G	ERMAN	ITE 215	_ 4.	Line)						e)		ing (Check Ap					
	Street) PLYMOUTH PA MEETING PA		19462											an One Repor	I		
(City) (State) (Zip)				_ R	Rule 10b5-1(c) Transaction Indication												
Table I - Non-Deriva       1. Title of Security (Instr. 3)     2. Transa Date (Month/D)					ative Securities Action 2A. Deemed Execution Date,			Code (Instr. 5) ar) 8)		neficiall	y Owned	nt of 6. es Fo ally (D following (I)	m: Direct or Indirect Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
			Table II - Deriv	Derivative Se		curities Acr		Code V		(A) or (D)	Price	Transact (Instr. 3 a	ion(s)				
								s, options,				Owneu					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactior Code (Instr. 8)				6. Date Exer Expiration D (Month/Day/ <sup>*</sup>	ate	d 7. Title and Amou of Securities Underlying Derivative Securi (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares						
Stock Option	\$30.69	01/24/2024		A		47,750		(1)	01/24/2034	Common Stock	47,750	\$0	47,750	D			
Restricted Stock Unit	(2)	01/24/2024		A		10,000		(2)	(2)	Common Stock	10,000	\$0	10,000	D			

## Explanation of Responses:

1. The stock option vests with respect to 25% of the underlying shares on January 24, 2025, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date.

2. The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date.

<u>/s/ Christian Ulrich, Attorney-</u> <u>in-Fact</u> <u>01/26/2024</u>

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.